Abstract

Ezrin, as encoded by the EZR gene, is a member of the Ezrin/Radixin/Moesin (ERM) family. The ERM family includes three highly related actin filament binding proteins, Ezrin, Radixin, and Moesin. These three members share similar structural properties containing an N-terminal domain named FERM, a central helical linker region, and a C-terminal domain that mediates the interaction with F-actin. Ezrin protein is highly regulated through the conformational change between a closed, inactivate form and an open, active form. As a membrane-cytoskeleton linker protein, Ezrin facilitates numerous signal transductions in tumorigenesis and mediates diverse essential functions through interactions with a variety of growth factor receptors and adhesion molecules. Emerging evidence has demonstrated that Ezrin is an oncogene protein, as high levels of Ezrin are associated with metastatic behavior in various types of cancer. The diverse functions attributed to Ezrin and the understanding of how Ezrin drives the deadly process of metastasis are complex and often controversial. Here by reviewing recent findings across a wide spectrum of cancer types we will highlight the structures, protein interactions and oncogenic roles of Ezrin as well as the emerging therapeutic agents targeting Ezrin. This review provides a comprehensive framework to guide future studies of Ezrin and other ERM proteins in basic and clinical studies.

Highlights

  • Cancer is one of the most debilitating diseases worldwide

  • We summarized the oncogenic roles of Ezrin and its pathophysiological roles and potential pharmacological regulators in a wide range of cancer types

  • Our understanding of Ezrin as a potential drug target is strongly influenced by the idea that Ezrin is commonly proved to promote tumor metastasis and predicts poor prognosis in different types of cancers

Read more

Summary

Introduction

Cancer is one of the most debilitating diseases worldwide. The molecular mechanisms of carcinogenesis provide essential implications for potential prevention and treatment of cancers. Phosphorylation of the C-terminal threonine residue (Thr567) is the key step to activate Ezrin, which allows the actin filament binding domains to interact with other proteins and break head-to-tail associations (Figure 1B; Matsui et al, 1998). Targeting Ezrin phosphorylation and actin binding activity provides a new therapeutic direction for clinical cancer interventions.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call